Table.
Characteristics of Included Studiesa
| Serial No. | Reference, year | Country | Study Period | Type of Study | N | Age (y)b | Female (%) | Severity of Infection | Hospitalization | Follow-up (d) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | An et al,13 2020 | China | 1/17/20-1/24/20 | Case series | 9 | 35.8 (28-45) | 44 | NS | ( ) | 10-17 |
| 2 | Chan et al,14 2020 | China | 1/10/20-1/15/20 | Case series | 6 | 50 (20-66) | 50 | ( ) | All | ( ) |
| 3 | Chang et al,15 2020 | China | 1/16/20-1/29/20 | Case series | 13 | 34 (34-48) | 23.1 | ( ) | No | 20 |
| 4 | Chen et al,16 2020 | China | 1/1/20-1/20/20 | Case series | 99 | 55 (21-82) | 32 | ( ) | All | 16-25 |
| 5 | Chen et al,17 2020 | China | ( ) | Case series | 9 | 54-25 | 77.8 | NS | All | 13 |
| 6 | Chen et al,18 2020 | China | 1/1/20-3/11/20 | Case series | 145 | 47.5±14.6 | 54.5 | B | All | Up to 69 |
| 7 | Cheung et al,5 2020 | Hong Kong | 2/2/20-2/29/20 | Case series | 59 | 58.5 (22-96) | 54.2 | ( ) | ( ) | ( ) |
| 8 | Cholankeril et al,19 2020 | US | 3/4/20-3/24/20 | Case series | 116 | 50 (35-67) | 46.5 | ( ) | All | ( ) |
| 9 | C-NERC,20 2020 | South Korea | 1/10/20-2/14/20 | Case series | 28 | 42.6 (20-73) | 46.1 | ( ) | All | 12.7 (range, 8-19) |
| 10 | C-NIRST,21 2020 | Australia | Until 3/14/20 | Case series (national database) | 295 | 47 (0-94) | 50 | ( ) | 225 | Up to 3/14/20 |
| 11 | Fan H et al,22 2020 | China | 12/30/19-2/16/20 | Case series | 101 | 65 (24-83) | 36.6 | S | All | ( ) |
| 12 | Fernandez-Ruiz et al,23 2020 | Spain | 3/5/20-3/23/20 | Case series | 17 | 71 (38-80) | 24 | ( ) | All | ( ) |
| 13 | Gritti et al,24 2020 | Italy | 3/11/20-3/24/20 | Case series | 21 | 64 (48-75) | 14.3 | ( ) | All | 8 (median) |
| 14 | Guan et al,25 2020 | China | 12/11/19-1/29/20 | Retrospective cohort | 1099 | 47 (35-58) | 41.9 | B | All | 13 |
| 15 | Hajifathalian et al,26 2020 | US | 3/4/20-4/16/20 | Case series | 1059 | 61±18 | 42.3 | B | 768 | Up to 34 |
| 16 | Han et al,27 2020 | China | 2/13/20-2/29/20 | Retrospective cohort | 206 | 62.5±32.5 | 55.8 | NS | All (for monitoring, quarantine) | 19-35 |
| 17 | Hsih et al,28 2020 | Taiwan | 1/20/20-2/19/20 | Case series | 2 | 45 (39-51) | 50 | ( ) | All | 35 |
| 18 | Huang et al,29 2020 | China | 12/16/19-1/2/20 | Prospective cohort | 41 | 49 (41-58)c | 27 | NS | All | ( ) |
| 19 | Huang et al,30 2020 | China | 1/21/20-2/1/20 | Case series | 11 | NA | 72.7 | ( ) | ( ) | ( ) |
| 20 | Huang et al,31 2020 | China | NA | Case series | 2 | 73.5 (73-74) | 100 | NS | All | 9 |
| 21 | Huang et al,32 2020 | China | 12/21/19-1/8/20 | Case series | 34 | 56.2 (26-88) | 58.8 | B | 33 | ( ) |
| 22 | Jin et al,33 2020 | China | 1/17/20-2/8/20 | Case series | 651 | 46.4±14.19 | 49.1 | B | All | ( ) |
| 23 | Kim ES et al,34 2020 | Korea | 1/19/20-2/17/20 | Case series | 28 | 40 (20-73) | 46.4 | B | All | Median time of off-isolation/discharge was 18.5 d after symptom onset (range, 11-27) |
| 24 | Klopfenstein et al,35 2020 | France | 3/1/20-3/17/20 | Case series | 114 | 56±18 | 59 | ( ) | ( ) | ( ) |
| 25 | Kluytmans et al,36 2020 | the Netherlands | 3/7/20-3/12/20 | Case series | 86 | 49 (22-66) | 83 | ( ) | 2 | 8 (range, 1-20) |
| 26 | Kuang et al,37 2020 | China | 1/1/20-2/10/20 | Retrospective cohort | 944 | 47 (21-96) | 49.6 | ( ) | All | ( ) |
| 27 | Liu et al,38 2020 | China | 12/30/19-1/24/20 | Case series | 137 | 57 (20-83) | 54.4 | ( ) | All | ( ) |
| 28 | Kujawski et al,39 2020 | US | 1/20/20-2/2/20 | Case series | 12 | 53 (21-68) | 33.3 | B | 7 | 1-14 |
| 29 | Lechien et al,40 2020 | Europe | ( ) | Case series | 417 | 36.9 (19-77) | 63.1 | ( ) | ( ) | ( ) |
| 30 | Li et al,41 2020 | China | 1/20-2/20 | Case series | 83 | 45±12.3) | 47 | B | All | ( ) |
| 31 | Lin et al,42 2020 | China | 1/17/20-2/15/20 | Case series | 95 | 45.3 | 52.6 | ( ) | ( ) | ( ) |
| 32 | Liu et al,43 2020 | China | 1/11/20-1/20/20 | Case series | 12 | 49 (10-72) | 33 | B | All | ( ) |
| 33 | Luo et al,4 2020 | China | 1/1/20-2/20/20 | Case series | 1141 | 53.8 | 44 | B | All | ( ) |
| 34 | Nobel et al,44 2020 | US | 3/10/20-3/21/20 | Case control | 278 | ( ) | 48 | B | 207 | 8 |
| 35 | Pan et al,45 2020 | China | 1/12/20-2/6/20 | Retrospective cohort | 21 | 35 (21-59) | 71.4 | NS | All | 26 |
| 36 | Pan et al,46 2020 | China | 1/18/20-2/28/20 | Retrospective cohort | 103 | 52 | 47.5 | B | All | 20-61 |
| 37 | Pung et al,47 2020 | Singapore | ( )-2/15/20 | Case series | 17 | 40 (36-51) | 59 | ( ) | All | ≥22 |
| 38 | Redd et al,48 2020 | US | Until 4/2/20 | Retrospective cohort | 318 | 63.4±16.6 | 45.3 | B | All | ( ) |
| 39 | Ren et al,49 2020 | China | 12/18/19-12/29/19 | Case series | 5 | 53.6 (41-65) | 40 | S | All | 17 |
| 40 | Shi et al,50 2020 | China | 12/20/19-1/23/20 | Retrospective cohort | 81 | 49.5 (25-81) | 48 | NS | All | ( ) |
| 41 | Shi et al,51 2020 | China | 1/20/20-2/10/20 | Retrospective cohort | 416 | 64 (21-95) | 50.7 | ( ) | All | ( ) |
| 42 | Shu et al,52 2020 | China | 2/13/20-2/29/20 | Retrospective cohort | 545 | 50 (38-58) | 51.6 | NS | All | ( ) |
| 43 | Siegel et al,53 2020 | US | 2/20 | Case series | 3 | 38.6 (26-50) | 0 | ( ) | All | 9 |
| 44 | Song et al,54 2020 | China | 1/20/20-1/27/20 | Case series | 51 | 49±16 | 50.9 | ( ) | All | 5 |
| 45 | Spiteri et al,55 2020 | Italy | 1/24/20-2/21/20 | Case series | 38 | 42 (2-81) | 34.2 | ( ) | 35 | Up to 20 |
| 46 | Tabata et al,56 2020 | Japan | 2/11/20-2/25/20 | Case series | 104 | 68 (25-93) | 53.3 | B | 10 | 3-15 (median, 10) |
| 47 | Wan et al,57 2020 | China | 2/12/20-3/6/20 | Case series | 230 | 47.5 (7-90) | 44 | B | All | ( ) |
| 48 | Wang et al,58 2020 | China | 1/1/20-1/28/20 | Case series | 138 | 56 (22-92) | 45.7 | B | All | ( ) |
| 49 | Wang et al,59 2020 | China | 1/21/20-2/5/20 | Case series | 18 | 39 (29-55) | 5.5 | B | All | 3-18 |
| 50 | Wang et al,60 2020 | China | 1/31/20-2/12/20 | Case series | 26 | 42.0 (33.5-53.3) | 57 | ( ) | All | ( ) |
| 51 | Wang et al,61 2020 | China | 1/1/20-2/6/20 | Case series | 339 | 69 (65-76) | 49.8 | B | All | 28 |
| 52 | Wang et al,62 2020 | China | 2/7/20-2/12/20 | Case series | 1012 | 50 (16-89) | 48.2 | ( ) | All | 24 |
| 53 | Wang et al,63 2020 | China | 1/21/20-1/24/20 | Case series | 4 | 47.5 (19-63) | 25 | ( ) | All | ( ) |
| 54 | Wei et al,64 2020 | China | 1/19/20-2/7/20 | Case series | 84 | 37 (24-74) | 66.6 | ( ) | All | 13-32 |
| 55 | Wolfel et al,65 2020 | Germany | 1/23/20-( ) | Case series | 17 | 40 (36-51) | 58.8 | ( ) | All | ( ) |
| 56 | Wu et al,66 2020 | China | 1/22/20-2/14/20 | Retrospective cohort | 80 | 46.1 (30.7-61.5)c | 51.3 | ( ) | All | 24 |
| 57 | Wu et al,67 2020 | China | 1/20-2/20 | Case series | 80 | 44±11 | 47.5 | ( ) | All | ( ) |
| 58 | Wu et al,68 2020 | China | 1/16/20-3/15/20 | Case series | 74 | ( ) | 24.3 | ( ) | All | ( ) |
| 59 | Xia et al,69 2020 | China | ( ) | Case series | 10 | 56.5±11.16 | 40 | ( ) | All | ( ) |
| 60 | Xiao et al,70 2020 | China | 2/1/20-2/14/20 | Case series | 73 | 43 (10 mo-78 y) | 65.7 | B | All | 26 |
| 61 | Xie et al,71 2020 | China | 2/2/20-2/23/20 | Case series | 79 | 60.0 (48.0-66.0) | 44.3 | B | All | 11.9 |
| 62 | Xiong et al,72 2020 | China | 1/11/20-2/5/20 | Case series | 42 | 49.5 (26-75) | 40.5 | NS | All | 22 |
| 63 | Xu et al,73 2020 | China | 1/23/20-2/4/20 | Case series | 90 | 50 (18-86) | 56.6 | B | All | ( ) |
| 64 | Xu et al,74 2020 | China | 1/10/20-1/26/20 | Case series | 62 | 41 (32-52) | 44 | NS | All | 17 |
| 65 | Yang F et al,75 2020 | China | 1/1/20-4/15/20 | Case series | 52 | 63 (34-98) | 46.2 | B | All | 41 |
| 66 | Yang et al,76 2020 | China | 12/24/19-1/26/20 | Case series | 52 | 59.7±13.3 | 33 | S | All | 15-48 |
| 67 | Young et al,77 2020 | Singapore | 1/23/20-2/3/20 | Case series | 18 | 47 (31-73) | 50 | NS | All | 23-34 |
| 68 | Yu et al,78 2020 | China | 1/20/20-1/23/20 | Case series | 4 | 74.5 (65-88) | 50 | B | ( ) | 18 |
| 69 | Zhang et al,79 2020 | China | 1/2/20-2/10/20 | Case series | 221 | 55.0 (39.0-66.5) | 51 | B | All | 6-45 |
| 70 | Zhang et al,80 2020 | China | 12/19-2/16/20 | Case series | 140 | 57 (25-87) | 50 | B | All | ( ) |
| 71 | Zhang et al,81 2020 | China | 1/27/20-2/10/20 | Case series | 14 | 41 (18-87) | 50 | ( ) | All | 1-14 |
| 72 | Zhao et al,82 2020 | China | 1/2/20-2/5/20 | Retrospective cohort | 19 | 48 (27-56) | 42.1 | ( ) | All | ( ) |
| 73 | Zhao et al,83 2020 | China | ( ) | Case series | 101 | 44.4 (17-75) | 44.5 | B | All | ( ) |
| 74 | Zhao et al,84 2020 | China | 1/16/20-2/10/20 | Case series | 91 | 46 () | 46.2 | B | All | 1-26 |
| 75 | Zhou et al,85 2020 | China | 12/29/19-1/31/20 | Retrospective cohort | 191 | 56 (46-67) | 38 | S | All | ( ) |
| 76 | Zhou et al,86 2020 | China | 1/16/20-1/30/20 | Case series | 62 | 52.8 (30-77) | 37.1 | ( ) | All | 14 |
| 77 | Zhou et al,87 2020 | China | 12/20/19-2/9/20 | Case series | 254 | 50.6 (15-87) | 54.7 | ( ) | All | ( ) |
| 78 | Zou et al,88 2020 | China | 1/7/20-1/26/20 | Case series | 18 | 59 (26-76) | 50 | B | All | ( ) |
a
( ) = missing; All = if all were hospitalized, number represents patients who were hospitalized; B = both; C-NERC = COVID-19 National Emergency Response Center; C-NIRST = COVID-19 National Incident Room Surveillance Team; NA = not available; NS = nonsevere; S = severe.
b
Represented as median (range) or mean ± SD, unless otherwise specified.
c
Represented as median (interquartile range).